The six new drugs FDA approved in October

Among the six new molecular entities FDA approved in October were a pair of ulcerative colitis therapies from Pfizer and Eli Lilly, and two autoimmune disease products from UCB, one for plaque psoriasis and one for myasthenia gravis.

Both of the ulcerative colitis therapies, Velsipity etrasimod from Pfizer Inc. (NYSE:PFE) and Omvoh mirikizumab from Eli Lilly and Co. (NYSE:LLY), are indicated to treat moderate-to-severe disease...